Woo Young Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Woo Young Kim has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Bu Gyeom Kim
Graduate School of Medicine, College of Medicine, Korea University, Seoul 08308, Korea
21 shared publications - Sang Cheul Oh
Division of Oncology, Department of Internal Medicine, Korea University College of Medicine, Korea University Guro Hospital, Seoul, Republic of Korea
21 shared publications - Sun Il Lee
Department of Surgery, Korea University Guro Hospital, Korea University College of Medicine, Seoul 08308, Korea
21 shared publications - Bo Ram Kim
Department of Oncology, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Republic of Korea
20 shared publications - Dae Yeong Kim
Department of Oncology, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Republic of Korea
20 shared publications - Sanghee Kang
Department of Surgery, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Republic of Korea
20 shared publications
Latest Publications
- 2 September 2026
- Published by Elsevier in Clinical Breast Cancer
- Vol. 26 (10) , 169-174
Clinical Outcomes and Chemoprevention in High-Risk Breast Lesions: A Comparison of Atypical Ductal Hyperplasia and Lobular Carcinoma In Situ
- 2 September 2026
- Published by Elsevier in Clinical Breast Cancer
- Vol. 26 (10) , 169-174
Clinical Outcomes and Chemoprevention in High-Risk Breast Lesions: A Comparison of Atypical Ductal Hyperplasia and Lobular Carcinoma In Situ
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Cannabidiol Enhances Atezolizumab Efficacy by Upregulating PD-L1 Expression via the cGAS–STING Pathway in Triple-Negative Breast Cancer Cells
Primer sequence for ChIP-PCR assay
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Cannabidiol Enhances Atezolizumab Efficacy by Upregulating PD-L1 Expression via the cGAS–STING Pathway in Triple-Negative Breast Cancer Cells
Primer sequence for ChIP-PCR assay
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Cannabidiol Enhances Atezolizumab Efficacy by Upregulating PD-L1 Expression via the cGAS–STING Pathway in Triple-Negative Breast Cancer Cells
Synergistic effects of CBD and anti-PD-L1 mAb in vivo experiments
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Cannabidiol Enhances Atezolizumab Efficacy by Upregulating PD-L1 Expression via the cGAS–STING Pathway in Triple-Negative Breast Cancer Cells
Synergistic effects of CBD and anti-PD-L1 mAb in vivo experiments
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Cannabidiol Enhances Atezolizumab Efficacy by Upregulating PD-L1 Expression via the cGAS–STING Pathway in Triple-Negative Breast Cancer Cells
CBD-induced PD-L1 expression in murine TNBC cells
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Cannabidiol Enhances Atezolizumab Efficacy by Upregulating PD-L1 Expression via the cGAS–STING Pathway in Triple-Negative Breast Cancer Cells
CBD-induced PD-L1 expression in murine TNBC cells
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Cannabidiol Enhances Atezolizumab Efficacy by Upregulating PD-L1 Expression via the cGAS–STING Pathway in Triple-Negative Breast Cancer Cells
CBD induced immunogenic cell death in TNBC cells
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Cannabidiol Enhances Atezolizumab Efficacy by Upregulating PD-L1 Expression via the cGAS–STING Pathway in Triple-Negative Breast Cancer Cells
CBD induced immunogenic cell death in TNBC cells
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Cannabidiol Enhances Atezolizumab Efficacy by Upregulating PD-L1 Expression via the cGAS–STING Pathway in Triple-Negative Breast Cancer Cells
CBD regulates immune checkpoint molecules in breast cancer cell lines
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Cannabidiol Enhances Atezolizumab Efficacy by Upregulating PD-L1 Expression via the cGAS–STING Pathway in Triple-Negative Breast Cancer Cells
CBD regulates immune checkpoint molecules in breast cancer cell lines
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Cannabidiol Enhances Atezolizumab Efficacy by Upregulating PD-L1 Expression via the cGAS–STING Pathway in Triple-Negative Breast Cancer Cells
The combination of CBD and atezolizumab stimulated an anti-cancer immune response in a co-culture system
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Cannabidiol Enhances Atezolizumab Efficacy by Upregulating PD-L1 Expression via the cGAS–STING Pathway in Triple-Negative Breast Cancer Cells
The combination of CBD and atezolizumab stimulated an anti-cancer immune response in a co-culture system
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Cannabidiol Enhances Atezolizumab Efficacy by Upregulating PD-L1 Expression via the cGAS–STING Pathway in Triple-Negative Breast Cancer Cells
Antibodies for cell surface PD-L1 measurement
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Cannabidiol Enhances Atezolizumab Efficacy by Upregulating PD-L1 Expression via the cGAS–STING Pathway in Triple-Negative Breast Cancer Cells
Antibodies for cell surface PD-L1 measurement
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Cannabidiol Enhances Atezolizumab Efficacy by Upregulating PD-L1 Expression via the cGAS–STING Pathway in Triple-Negative Breast Cancer Cells
Antibodies for western blot analysis
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Cannabidiol Enhances Atezolizumab Efficacy by Upregulating PD-L1 Expression via the cGAS–STING Pathway in Triple-Negative Breast Cancer Cells
Antibodies for western blot analysis